Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014627 | 1.00 | MAOA (0.52) | MAOAMAOBTRPV1SIGMAR1MAPT | |
| SCHEMBL6014611 | 1.00 | MAOA (0.52) | MAOAMAOBTRPV1SIGMAR1MAPT | |
| SCHEMBL6014614 | 1.00 | MAOA (0.52) | MAOAMAOBTRPV1SIGMAR1MAPT | |
| SCHEMBL6014551 | 0.98 | MAOA (0.54) | MAOAMAOBTRPV1SIGMAR1MAPT | |
| SCHEMBL6014548 | 0.98 | MAOA (0.54) | MAOAMAOBTRPV1SIGMAR1MAPT | |
| SCHEMBL4785068 | 0.92 | MAOA (0.50) | MAOAMAOBSIGMAR1HTR2AIDO1 | |
| SCHEMBL6014620 | 0.92 | MAOA (0.50) | MAOAMAOBSIGMAR1HTR2AIDO1 | |
| SCHEMBL3593459 | 0.83 | MAOA (0.56) | MAOAMAOBSIGMAR1MAPTRXFP1 | |
| SCHEMBL3585702 | 0.83 | MAOA (0.56) | MAOAMAOBSIGMAR1MAPTRXFP1 | |
| SCHEMBL3597857 | 0.83 | MAOA (0.56) | MAOAMAOBSIGMAR1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | MAOA 297/4885MAOB 402/4885TRPV1 3459/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | MAOA 297/4885MAOB 402/4885TRPV1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.